A UGT1A1 Genotype-Guided Dosing Study of Irinotecan Administered in Combination With 5-Fluorouracil/Leucovorin (FOLFIRI) and Cetuximab as First-Line Therapy in RAS Wild-Type Metastatic Colorectal Cancer Patients

Trial Profile

A UGT1A1 Genotype-Guided Dosing Study of Irinotecan Administered in Combination With 5-Fluorouracil/Leucovorin (FOLFIRI) and Cetuximab as First-Line Therapy in RAS Wild-Type Metastatic Colorectal Cancer Patients

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Irinotecan (Primary) ; Cetuximab; Fluorouracil; Folinic acid
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Dec 2016 Planned initiation date changed from 1 Nov 2015 to 1 Jun 2015.
    • 08 Dec 2016 Planned End Date changed from 1 Nov 2017 to 1 Aug 2016.
    • 08 Dec 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top